Cambridge Cognition Holdings plc (LON:COG) the neuroscience technology company, which develops and markets digital solutions to assess brain health, today announced its first commercial partnership for its recently launched NeuroVocalix™ voice biomarker technology.
NeuroVocalix enables the remote assessment of voice-based cognitive measures. In the first contract the technology will be licensed for use in an innovative virtual clinical trial with a global pharmaceutical company.
The four week study will include two verbal NeuroVocalix cognitive tests delivered alongside Cambridge Cognition’s CANTAB and Cognition Kit assessments, all administered directly to study participants on their smartphones.
The collection of objective and frequent cognitive data made possible by the Company’s near-patient digital health technologies enable pharmaceutical sponsors to identify efficiencies in both time and cost.
Traditional methods of clinical trials, which use multiple study sites and require multiple patient visits to sites, have high attrition rates with as many as 40% of Phase III trial participants dropping out.
Virtual clinical trials represent a relatively new method of collecting safety and efficacy data, using digital technologies to conduct clinical trials from the comfort of the patients’ homes to keep participants engaged with the study, leading to better data quality and shorter timelines.
With the Company’s NeuroVocalix, CANTAB Recruit and Cognition Kit products all being delivered to patients’ own devices, sponsors can now administer cognitive outcome assessments virtually at all stages of a clinical trial, from recruitment to post-marketing.
Dr Steven Powell, Chief Executive Officer, Cambridge Cognition Holdings said:
“We are pleased to confirm this first contract for use of the novel voice platform in an industry sponsored clinical trial so soon after its launch. This demonstrates our continued commitment to innovative R&D projects, which will benefit our pharmaceutical clients and shows our ability to commercialise new neuroscience technology products rapidly.”
